



ORIGINAL ARTICLE

## Drug-eluting stent thrombosis in the treatment of chronic total coronary occlusions: Incidence, presentation and related factors. Data from the CIBELES trial



Eduardo Arroyo-Úcar<sup>a</sup>, Raul Moreno<sup>a,\*</sup>, Eulogio García<sup>b</sup>, Rui Teles<sup>c</sup>, Jose-Ramon Rumoroso<sup>d</sup>, Henrique Cyrne Carvalho<sup>e</sup>, Francisco Javier Goicolea<sup>f</sup>, José Moreu<sup>g</sup>, Josefa Mauri<sup>h</sup>, Manel Sabaté<sup>i</sup>, Vicente Mainar<sup>j</sup>, Lino Patricio<sup>k</sup>, Mariano Valdés<sup>l</sup>, Felipe Fernández-Vázquez<sup>m</sup>, Angel Sánchez-Recalde<sup>a</sup>, Guillermo Galeote<sup>a</sup>, Santiago Jimenez-Valero<sup>a</sup>, Manuel Almeida<sup>c</sup>, Esteban López de Sa<sup>a</sup>, Luis Calvo<sup>a</sup>, Ignacio Plaza<sup>a</sup>, Jose-Luis Lopez-Sendón<sup>a</sup>, Jose-Luis R. Martín<sup>n</sup>, for the CIBELES investigators

<sup>a</sup> Hospital Universitario La Paz, Madrid, Spain

<sup>b</sup> Hospital Clinico, Madrid, Spain

<sup>c</sup> Hospital de Santa Cruz, Lisbon, Portugal

<sup>d</sup> Hospital de Galdakao, Bilbao, Spain

<sup>e</sup> Hospital de Santo Antonio, Porto, Portugal

<sup>f</sup> Hospital Puerta de Hierro, Majadahonda, Spain

<sup>g</sup> Hospital Virgen de la Salud, Toledo, Spain

<sup>h</sup> Hospital German Trias I Pujol, Badalona, Spain

<sup>i</sup> Hospital Santa Creu I Sant Pau, Barcelona, Spain

<sup>j</sup> Hospital General, Alicante, Spain

<sup>k</sup> Hospital de Santa Marta, Lisboa, Portugal

<sup>l</sup> Hospital Virgen de la Arrixaca, Murcia, Spain

<sup>m</sup> Complejo Hospitalario, León, Spain

<sup>n</sup> Research Manager, School of Biomedical and Health Sciences, Universidad Europea de Madrid, Spain

Received 15 July 2014; accepted 16 August 2014

Available online 14 February 2015

### KEYWORDS

Stent;  
Thrombosis;  
Everolimus;

### Abstract

*Introduction and Objectives:* The aim of this study was to analyze the incidence of drug-eluting stent thrombosis (sirolimus or everolimus) in patients with chronic total coronary occlusions (CTO) and to determine its clinical implications and related factors.

\* Corresponding author.

E-mail address: [raulmorenog@hotmail.com](mailto:raulmorenog@hotmail.com) (R. Moreno).

*Sirolimus*;  
Chronic total  
coronary occlusion

**Methods:** Data from the 12-month follow-up of the 207 patients included in the CIBELES trial with CTO were analyzed.

**Results:** Stent thrombosis occurred in three patients, two definite and one probable (overall thrombosis rate: 1.4%). However, there were no cases of death or Q-wave myocardial infarction. In univariate analysis, patients with a higher incidence of stent thrombosis were those in whom the target vessel was the left anterior descending, who had single-vessel disease, were assigned to treatment with sirolimus-eluting stents, and those with smaller minimum luminal diameter immediately after the procedure. In multivariate analysis, the only independent predictor of stent thrombosis was minimal luminal diameter immediately after the procedure.

**Conclusions:** The rate of drug-eluting stent thrombosis in patients with CTO is relatively low (1.4%). The only independent predictor of stent thrombosis in this context was minimal luminal diameter after the procedure and the clinical presentation was in all cases relatively benign.

© 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.

## PALAVRAS-CHAVE

*Stent*;  
Trombose;  
Everolimus;  
*Sirolimus*;  
Oclusão coronária  
crónica total

## Trombose do *stent* fármaco ativo no tratamento da oclusões totais coronárias: incidência, apresentação e fatores relacionados. Os dados do ensaio Cibeles

### Resumo

**Introdução e objetivos:** o objetivo do nosso estudo foi analisar a incidência de trombose de *stent* com eluição de fármaco (*sirolimus* ou *everolimus*) em pacientes com oclusões coronárias crónicas e identificar as suas implicações clínicas e fatores relacionados.

**Métodos:** 12 meses de acompanhamento dos 207 pacientes incluídos no ensaio Cibeles com oclusão total coronária crónica.

**Resultados:** a trombose de *stent* ocorreu em três doentes: duas definitivas e uma provável (taxa global de trombose 1,4%). No entanto, não surgiu nenhum caso de morte ou enfarte do miocárdio com onda Q. Na análise univariada, os doentes com maior incidência de trombose de *stent* foram aqueles em que o vaso-alvo foi a descendente anterior, os que tinham a doença de um vaso, os que foram considerados para tratamento com *stent* com *sirolimus*, e aqueles com diâmetro luminal mínimo menor imediatamente após o procedimento. Na análise multivariada, o único preditor independente de trombose do *stent* foi o diâmetro luminal mínimo imediatamente após o procedimento.

**Conclusões:** a taxa de trombose de *stent* farmacológico em pacientes com oclusão coronária crónica foi relativamente baixa (1,4%).

O único preditor independente de trombose de *stent* neste contexto foi o diâmetro luminal mínimo após o procedimento, tendo a apresentação clínica em todos os casos sido relativamente benigna.

© 2014 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados.

### List of abbreviations

CTO	chronic total occlusion
ST	stent thrombosis
EES	everolimus-eluting stent
SES	sirolimus-eluting stent
DES	drug-eluting stent
BMS	bare-metal stent

## Introduction

Chronic total coronary occlusions (CTO) constitute one of the most complex and challenging therapeutic scenarios

for an interventional cardiologist, due not only to the technical complexity of the lesion and the need for specific operator skills, but also to the many complications that can occur during and after the procedure.<sup>1-4</sup> Stent thrombosis (ST) represents the most important clinical complication due to the high rate of death and/or myocardial infarction.<sup>5</sup> Its pathophysiology includes various factors related to the device itself, the procedure and the patient.<sup>6</sup>

It has been traditionally considered that one of the factors associated with increased risk of ST is, as suggested by some studies,<sup>7,8</sup> the implantation of a drug-eluting stent (DES) in the context of a CTO. The aim of this study is to assess the incidence, clinical significance and timing of DES thrombosis in the treatment of CTO, given the lack of clear knowledge concerning the safety of these devices in this context.

Download English Version:

<https://daneshyari.com/en/article/3020131>

Download Persian Version:

<https://daneshyari.com/article/3020131>

[Daneshyari.com](https://daneshyari.com)